Fig. 5: Hederagenin sensitized cancer cells to cisplatin and paclitaxel by amplifying ROS stress. | Cell Death & Disease

Fig. 5: Hederagenin sensitized cancer cells to cisplatin and paclitaxel by amplifying ROS stress.

From: Hederagenin potentiated cisplatin- and paclitaxel-mediated cytotoxicity by impairing autophagy in lung cancer cells

Fig. 5

a Hederagenin and cisplatin combination induced excessive accumulation of undigested cargos (Transmission electron microscopy). NCI-H1299 cells were treated with either hederagenin (50 µM), cisplatin (25 µM), or both for 24 h. Then transmission electron microscopy was performed to observe the structure of the cells. Scale bar, 3 μm. b & c Compared to cisplatin (25 μM) treatment alone, pre-treatment with hederagenin (50 μM) significantly enhanced Cis-induced ROS production in NCI-H1299 (Q = 1.72) and NCI-1975 cells (Q = 3.77). Cells treated by H2O2 (50 μM) for 2 h was used as a positive control. d Co-treatment with hederagenin (50 μM) and paclitaxel (1 μM) induced significantly higher intracellular ROS level than paclitaxel (1 μM) treatment alone in NCI-H1299 cells (Q = 2.63). Cells treated by H2O2 (50 μM) for 2 h was used as a positive control. e & f Pre-treatment with hederagenin (50 μM) synergized Cis (25 μM)-induced growth inhibition in NCI-H1299 (Q = 1.24) and NCI-H1975 (Q = 1.49) cells. These effects were completely abolished by NAC (2 mM) treatment. The Q value between the Hed + Cis group and the NAC + Cis + Hed group is 0.74. g Pre-treatment with hederagenin (50 μM) synergized paclitaxel (1 μM)-induced growth inhibition in NCI-H1299 cells (Q = 1.28). The synergizing effect was completely reversed by NAC (2 mM) pre-treatment. The Q value between the Hed + PTX group and the NAC + PTX + Hed group is 0.72. **p < 0.01, ***p < 0.001, ANOVA with multiple comparisons. Cisplatin: Cis, paclitaxel: PTX, hederagenin: Hed.

Back to article page